MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/17588359261456684

Медицинская библиотека · Therapeutic advances in medical oncology · 2026

HLX07, a novel anti-EGFR antibody, for locally advanced and metastatic cutaneous squamous cell carcinoma: an open-label, multicenter, phase II trial.

Li Changxing, Zeng Kang, Zhu Dongyuan, Fan Zhengfu, Chen Yong, Chen Yu, Li Yong, Ji Mingkai, Duan Ping, Su Juan, Yang Jilong, Tang Yang, Zhang Mingjun, Wang Siyang, Yu Gengsheng, Huang Yisheng, Chen Rongyi, Hu Xuhui, Yang Futang, Yu Haoyu, Wang Qingyu, Li Jing, Zhu Jun

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Cutaneous squamous cell carcinoma (CSCC) accounts for 20% of all cutaneous cancers. Systemic treatment options for advanced CSCC (aCSCC) include immunotherapy, chemotherapy, and epidermal growth factor receptor (EGFR)-targeted therapy, although their efficacy is limited. HLX07 is a novel anti-EGFR antibody that showed preliminary anti-cancer activity and tolerability in phase I studies.

OBJECTIVES

To evaluate the efficacy and safety of HLX07 in patients with aCSCC.

DESIGN

This is a multicenter, open-label, two-part phase II study. In Part 1, patients with metastatic or locally aCSCC not amenable to surgery or curative radiotherapy received 1500 mg (group A) or 1000 mg (group B) HLX07 intravenously every 3 weeks. In Part 2, patients received HLX07 at dose level determined with Part 1 results.

METHODS

The primary endpoint was objective response rate (ORR) assessed by an independent radiology review committee (IRRC). Secondary endpoints included other efficacy endpoints, safety, pharmacokinetics, immunogenicity, and quality of life.

RESULTS

Here we focus on Part 1 data. As of April 30, 2024, 31 patients were enrolled (group A, 21; group B, 10). Most patients had metastatic disease (85.7%; 90.0%). Per IRRC assessments, ORR was 19.0% (95% confidence interval (CI), 5.5-41.9) for group A and 60.0% (26.2-87.8) for group B; median progression-free survival was 4.9 (95% CI, 1.4-6.5) and 7.9 (95% CI, 2.2-11.1) months, and median duration of response was 5.0 (95% CI, 2.9-not evaluable (NE)) and 7.4 (95% CI, 2.8-NE) months, respectively. Median overall survival was 11.8 months (95% CI, 5.9-NE) and not reached (95% CI, 2.2-NE). Grade ⩾3 treatment-related adverse events (TRAEs) occurred in 8 (38.1%) and 3 (30.0%) patients, respectively. No TRAE leading to death or treatment discontinuation was reported.

CONCLUSION

HLX07 monotherapy has demonstrated promising efficacy and a favorable safety profile in treating aCSCC, warranting further investigation in large-scale clinical studies.

TRIAL REGISTRATION: ClinicalTrials.gov NCT05238363.

Для цитирования: Li Changxing, Zeng Kang, Zhu Dongyuan, Fan Zhengfu, Chen Yong, Chen Yu, Li Yong, Ji Mingkai, Duan Ping, Su Juan, Yang Jilong, Tang Yang, Zhang Mingjun, Wang Siyang, Yu Gengsheng, Huang Yisheng, Chen Rongyi, Hu Xuhui, Yang Futang, Yu Haoyu, Wang Qingyu, Li Jing, Zhu Jun. HLX07, a novel anti-EGFR antibody, for locally advanced and metastatic cutaneous squamous cell carcinoma: an open-label, multicenter, phase II trial.. Therapeutic advances in medical oncology. 2026. DOI: 10.1177/17588359261456684.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.